TIM
STR
Arvids Ziedonis
Boston U., United States
Michael Roach
U. of Illinois at Urbana-Champaign, United States
Sina Khoshsokhan
U. of Colorado, Boulder, United States
Samantha Zyontz
Boston U. Questrom School of Business, United States
Elisabeth Hofmeister
Max Planck Institute for Innovation and Competition, Germany
Research and drug development within the life sciences has increasingly relied on advances in genomics to generate new outcomes and treatments. New technologies such as CRISPR offer tremendous opportunities for new therapeutics and treatments. Not surprisingly, new institutions, policy changes towards intellectual property protection, and firm strategies have arisen to facilitate and govern innovative activity within this emerging sphere. This presenter symposium assembles three studies that provide new and complementary vantage points on the emergence of institutions, policies, and firm strategies for the development and commercialization of genomics-based therapeutics.
Author: Samantha Zyontz – Boston U. Questrom School of Business
Author: Sina Khoshsokhan – U. of Colorado, Boulder
Author: Elisabeth Hofmeister – Max Planck Institute for Innovation and Competition